NCT06711055View on ClinicalTrials.gov

Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer

RecruitingOBSERVATIONAL

Enrollment

285

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

December 31, 2031

Study Completion Date

December 31, 2031

Conditions

HER2-positive Breast Cancer

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Shu Wang

OTHER